Maine Bill Seeks to Legalize Therapeutic Use of Psilocybin
Maine could soon become the second U.S. state to legalize the use of medicinal psilocybin for therapeutic use.
Jennifer Walker-Journey is a lifelong writer of most anything, including travel destinations, exotic foods and beverages, and characters with far more fascinating lives than hers. But her strongest interests lie in telling the story of psychedelic medicines and the life-changing therapeutic possibilities they hold.
Maine could soon become the second U.S. state to legalize the use of medicinal psilocybin for therapeutic use.
A follow-up study has found long-term relief from anxiety and depression related to cancer diagnoses with use of psilocybin treatment.
This week in psychedelic business news: Cybin’s experimental psychedelic takes aim at alcohol use disorder, Numinus seeks volunteers for its natural psilocybin extract, and another psychedelic company trades on Nasdaq. Toronto-based biotech company Cybin Inc., announced it will focus its proprietary deuterated psychedelic tryptamine CYB003 for the treatment of alcohol use disorder (AUD), a condition that […]
Beckley Psytech and Fluence have partnered on a first of its kind training for 5-meo-DMT psychedelic treatment and therapy.
Ketamine may be a useful treatment for diabetes and obesity, according to a new patent filed by psychedelic company PharmTher.
Should psychedelics be legal? That was the topic of an expert-led debate featured on the Intelligence² Debates podcast.
A new campaign, #natureheals promotes psychedelics for veterans suffering from PTSD and other mental health issues.
A new psychedelic hotline, the Fireside Project, aims to provide peer support for people under the influence of psychedelic substances.
Interactive or lucid dreaming may be as beneficial for mental health as lucid dreaming, new research finds.
This week in psychedelic business news: Atai to raise $100 million, Silo’s psilocybin nasal spray, and more.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.